Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up study

Table 1 Patients characteristics according to groups of eGFR (N = 669)

Demographic data	eGFR: < 45.0 ml/min 1.73 m² N = 191	eGFR: 45.0-59.9 ml/min 1.73 m² N = 162	eGFR: 60.0 – 74.9 ml/min 1.73 m² N = 176	eGFR: ≥75.0 ml/min1.73 m² N = 140	P value
Clinical variables:
Age, years	78 (63–91)	75 (56–89)	72 (55–90)	68 (46–84)	<0.001
Female sex,%	45	43	30	34	0.006
BMI, kg/m²	25 (19–26, 26–36)	26 (17–37)	26 (18–34)	27 (20–41)	0.058
Smoking,%	20	23	31	43	<0.001
History of HF,%	76	76	63	54	<0.001
NYHA Class,%:					0.052
I	7	9	15	15
II	65	65	62	65
III	25	25	19	20
IV	3	1	4	0
Comorbidity:
Diabetes,%	22	15	13	15	0.049
COPD,%	20	19	23	26	0.111
IHD,%	54	58	45	39	0.002
Previous MI,%	32	35	30	25	0.139
Hypertension,%	32	32	25	31	0.484
Chronic AF,%	26	21	28	19	0.313
Paroxysmal AF,%	19	22	21	21	0.801
Echocardiographic variables:
WMI, index:	1.2 (0.5–2.0)	1.1 (0.5–2.0)	1.3 (0.5–2.0)	1.4 (0.6–2.0)	0.093
LVEDD, mm	57 (42–75)	59 (41–77)	58 (42–70)	57 (42–78)	0.878
A, m/s	0.63 (0.30–1.15)	0.76 (0.30–1.33)	0.62 (0.32–1.03)	0.62 (0.33–0.96)	0.055
E/A-ratio	1.34 (0.56–3.37)	1.11 (0.57–3.11)	1.12 (0.58–3.03)	1.40 (0.60–3.12)	0.4639
Medication (discharge):
ACE-I,%	51	70	63	45	0.309
ARB,%	10	9	5	9	0.266
Beta blockers,%	49	57	45	42	0.097
Diuretics,%	95	93	89	89	0.017
Digoxin,%	37	39	47	36	0.634
Statin,%	17	20	16	23	0.470
Nitrates,%	28	23	12	17	0.001

eGFR = estimated glomerular filtration rate; BMI = Body Mass Index; History of HF = history of heart failure; NYHA class = New York Heart Association; COPD = chronic obstructive pulmonary disease; IHD = ischemic heart disease; Previous MI = previous myocardial infarction; Chronic AF = chronic atrial fibrillation; Paroxysmal AF = paroxysmal atrial fibrillation; WMI = wall motion index; LVEDD = left ventricular enddiastolic diameter; A = late atrial mitral Doppler peak flow velocity; E/A-ratio = the ratio of early (E) to late atrial (A) mitral Doppler peak flow velocity; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker.

ISSN: 1471-2369